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Simvastatin is an inhibitor of HM G-CoA reductase used in the treatment of hypercholes­
terolemia. In the present study simvastatin-induced contraction was observed in rat aortic 
thoracic rings, this effect increased when the endothelium was removed and when NO syn­
thase was blocked by L-NOARG (3 x  10“5 m ) .  The contractile effect of simvastatin on intact 
aortic rings diminished when cyclo-oxygenase was inhibited with indomethacin (10-5 m ) .  Also 
in the presence of endothelium, pretreatment with mevalonate (1 mM), the product of HMG- 
CoA reductase activity, significantly inhibited the contraction. In other experiments carried 
out on endothelium-removed preparations and in medium containing the calcium antagonist, 
diltiazem (10-5 and 10-6 m ) ,  the contraction dose-response curves were significantly reduced 
and the same happened in the presence of the inhibitor of sarcoplasmic reticulum Ca-2+-  
ATPase, cyclopiazonic acid (CPA) (3 x  10-6 m ) .
The results suggest that simvastatin might increase intracellular calcium concentration.
This effect could lead to an activation of NO synthase and cyclooxygenase pathways in endo­
thelial cells and to contraction in vascular smooth muscle cells. This rise in Ca2+ concentration 
could be due to an inhibition of isoprenoid synthesis prevented by mevalonate.
Introduction
Simvastatin is a drug widely used in the treat­
ment of hypercholesterolemia. This drug is an 
inhibitor of the rate-determining enzyme in the 
biosynthesis of cholesterol, 3-hydroxy-3-methyl- 
glutaryl-coenzyme A (HMG-CoA) reductase and 
has proved useful in the reduction of plasma low 
density lipoprotein (LDL). Clinical trials have de- 
mostrated that inhibitors of HMG-CoA reductase 
decrease cardiovascular-related morbidity and 
mortality (Vaughan et al., 1996).
In previous studies of our laboratory, we found 
that another HMG-CoA reductase inhibitor, lo- 
vastatin, was able to decrease blood pressure and 
had vasodilatatory effects in precontracted iso­
lated rat thoracic aorta (Bravo et al., 1998). It has 
also been demostrated that chronic treatment with 
simvastatin was able to improve endothelial func­
tion in spontaneously hypertensive rats (Alvarez 
de Sotomayor et al., 1999). In order to elucidate 
the mechanism of action of simvastatin, the direct 




Wistar male rats (250-300 g) were killed by a 
blow on the head. The descending thoracic aorta 
was rapidly dissected and placed in a modified 
Krebs-Henseleit solution (PSS), containing ( m M ) :  
NaCl 118, KC1 4.75, N aH C 0 3  25, M gS0 4  1.2, 
CaCl2  1.8, KH 2 P 0 4  1.2 and glucose 11. After ex­
cess fat and connective tissue were removed, the 
aortas were out cut into 2 -3  mm rings. Aortic 
rings were mounted under the basal tension of 1  
g in 20 ml organ baths containing PSS and at­
tached to a force-displacement transductor (H ar­
vard UF-1) and the signal was recorded by a Pow- 
erlab® data acquisition system (ADInstruments) 
to measure the contractile force. The tissue bath 
was maintained at 37 °C and bubbled with a 95% 
0 2 -5 %  C 0 2  ( v / v )  gas mixture. In some experi­
ments, the endothelium of the aorta was mechani­
cally removed by gently rubbing the inner surface. 
The absence of endothelium was confirmed by the 
absence of relaxing effects of acetylcholine (ACh 
1 0 ~ 6  m )  in aortic rings previously contracted by 
noradrenalin (NA 10 ' 5  m ) .  Each preparation was
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allowed to equilibrate for at least 90 min prior to 
start of experimental procedures, and during this 
period the incubation media was changed every 
2 0  min.
Dose-response curves of contraction were ob­
tained by addition of cumulative concentrations of 
simvastatin (10 - 7  to 10~ 4  m )  at 3-min intervals in 
the presence and absence of endothelium. The 
same experiments were carried out in the presence 
of N-w-nitro-L-arginine (L-N O A R G , 3 x 10“ 5  m ) ,  
indomethacin (10 - 5  m ) ,  mevalonate (1 m M ) ,  diltia- 
zem ( 1 0 ~ 6  m  or 1 0 - 5  m )  and cyclopiazonic acid 
(CPA, 3 x 10- 6  m )  in aortic rings. All results are 
expressed as a percentage of the maximal con­
traction of noradrenalin-induced responses.
Drugs
Indomethacin (l-[/?-chlorobenzoyl]-5-methoxy- 
2-methylindole-3-acetic acid), mevalonate ( d l - / 3 -  
hydroxy-/3-methyl-(5-valero-lactone), N-&»-nitro-L- 
arginine (N5-  [nitroamidino]-L-2,5-diaminopenta- 
noic acid), diltiazem (ds-(+)-3-(acetyloxy)-5-[2- 
(dimethyl-amino)ethyl]-2,3-dihydro-2-(4-meth- 
oxy-phenyl)-l,l-benzothiazepin-4 (5H) one) hy­
drochloride, cyclopiazonic acid (C 2 0 H 2 0 N 2 O 3 ) 
from Penicillium cyclopium, acetylcholine 
(C 7 H 1 6 N 0 2 C1) and noradrenalin (-)-arterenol 
(CsH uN O s.C^öO ö) were obtained from Sigma 
Chemical Co (St. Louis, MO, USA).
Simvastatin (2,2-dimethylbutanoate 1,2,3,7,8,8a- 
hexahydro-3,7-dimethyl-8-[2-tetrahydro-4-hydro- 
xy-6-oxo-2H-pyran-2-yl)ethyl]-l-naphthalenyl), 
was generously provided by Merck laboratories 
(New Jersey, USA). All drugs were dissolved in 
dimethylsulfoxide (DMSO) except N-co-nitro-L- 
arginine and diltiazem which were dissolved in dis­
tilled water. The final concentration of DMSO did 
not significantly affect the results.
Statistical analysis
Results are expressed as mean ± SEM of six 
preparations obtained from different animals. 
Analysis of variance (ANOVA) followed by the 
LSD (least significant difference) test were used 
for statistical analysis. P values <0.05 were con­
sidered to indicate a significant difference. Dose- 
response slopes were analysed to give the concen­
tration of simvastatin producing 50% of the maxi­
mum contractile response (ED50) using a linear 
regression analysis.
Results and Discussion
Addition of cumulative concentrations of sim­
vastatin ( 1 0 ~ 7  to 1 0 ~ 4  m )  induced dose-dependent 
contractions in isolated rat thoracic aorta with and 
without endothelium, reaching maximal tension 
values of 1.22 ± 0.08 g and 1.94 ± 0.12 g and the 
ED 5 0  values were 3.46 ± 0.56 x 10- 5  m  and 5.41 ± 
0.25 x 10- 6  m ,  respectively. In intact aortic rings, 
preincubation with L-NOARG (3 x 10~ 5  m )  signif­
icantly potentiated the contractions evoked by 
simvastatin (ED 5 0  = 3.62 ± 0.27 x 10- 6  m ) .  How­
ever, pretreatm ent of the aortic rings with indo­
methacin ( 1 0 ~ 5  m )  decreased the curve obtained 
with simvastatin alone underneath the control 
curve reaching only 30% of the maximal effect.
In the presence of mevalonate (1 m M ) ,  the pro­
duct of HMG-CoA reductase activity, simvastatin- 
induced contraction was almost abolished. When 
the experiments were carried out on endothelium- 
removed preparations and in a medium containing 
diltiazem (1 0 ~ 6  m  or 1 0 ~ 5  m ) ,  the curve obtained 
with simvastatin was significantly reduced, yield­
ing a higher effect at the highest dose of diltiazem 
assayed. Pretreatment with cyclopiazonic acid (3 x 
1 0 - 6  m )  diminished the contractile effect of sim­
vastatin on endothelium-intact preparations. The 
percent data are summarized in Table I.
The contractile effect induced by simvastatin in 
rat aortic thoracic rings increased when the endo­
thelium was removed, showing the involvement of 
endothelial factors in the mechanism of action of 
simvastatin. When NO synthase was blocked with 
L-NOARG, the contraction caused by simvastatin 
was enhanced, suggesting that NO is released in 
the presence of simvastatin, opposing its relaxant 
effect to the contraction. In this way, former expe­
riences have shown that NO is involved in some 
actions of statins (Laufs et al., 1998; Hernändez- 
Perera et al., 1998; Kaesemeyer et al., 1999). The 
contractile effect diminished when indomethacin 
inhibited cyclo-oxygenase, supporting the notion 
of a partial participation of contracting cyclo-oxy- 
genase-derived factors (endoperoxides and throm­
boxanes) in this effect. Both results together might 
be explained by an action of simvastatin in a cor- 
vengent point of both, NO synthase and cyclo-oxy-
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Table I. Percentage effect reached in response to simvastatin (10-7 -  10-4 m )  in aortic rings with (E(+)) and without 
endothelium (E (- ) ) .  In the absence of L-NOARG, indomethacin (IND O ), cyclopiazonic acid (CPA), diltiazem 
(DIL) and mevalonate (MV). Values are mean ± SEM of n = 6 experiments. *P<0.05;**P<0.01; ***P<0.001 vs 
control with endothelium. #P<0.05; # # P < 0 .0 1 ; # # # P 0 .0 0 1  vs control without endothelium.
Simvastatin (m) io-7 io-6 1 0 5 10"4
Control E(+) 0.7 ± 0.2 1.7 ± 1.0 28.7 ± 6.0 63.6 ± 7.7
Control E ( - ) 1.2 ± 0.5 15.1 ± 4.0 64.8 ± 5.9 *** 89.8 ± 3.8 *
L-NOARG (3 x 10~5 m )  E(+) 0.7 ± 0.6 17.3 ± 7.4 76.9 ± 11.2 *** 107.9 ± 9.8 ***
IN DO  (IO“5 m )  E(+) 0.9 ± 0.2 0.9 ± 0.3 9.6 ± 4.4 30.0 ± 6.6 **
MV (IO“3 m )  E(+) 1.8 ± 1.1 1.9 ± 1.1 2.4 ± 1.0 ** 13.9 ± 4.5 ***
CPA (3 x 10- 5 m )  E (- ) 1.7 ± 0.9 4.2 ± 1.1 # 18.8 ± 2.5 ## 38.3 ± 4.3 # # #
CPA (3 x 10- 6 m )  E (- ) 0.4 ± 0.2 0.6 ± 0.1 # 12.9 ± 2.2 # # # 44.7 ± 6.0 # # #
DIL (10- 5 m )  E (- ) 6.0 ± 3.0 3.8 ± 1.7 # 9.2 ± 2.2 # # # 23.3 ± 6.1 # # #







E (- ) ,  without endothelium.
genase pathways, like Ca2+ increment in endothelial 
cell, necessary for activation of NO synthase (Mon- 
cada et al., 1991) and phospholipase A 2  (Verbeij et 
al., 1981), and consequently cyclo-oxygenase. The 
presence of mevalonate, the metabolic product of 
HM G-CoA reductase (Goldstein and Brown
1990), almost abolished simvastatin-induced con­
traction, indicating the involvement of mevalonate 
pathway. In accordance with our hypothesis, some 
other reports showed that in vascular smooth mus­
cle cells, simvastatin has been able to increase tran­
siently cytosolic free Ca2+ concentration, being this 
effect prevented by the presence of mevalonate (Ng 
et al., 1994; Escobales et al., 1996).
Diltiazem, a calcium entry antagonist, and cyclo­
piazonic acid, a Ca2+-ATPase inhibitor, were effec­
tive in inhibiting the contractile response to sim­
vastatin, leading us conclude that both: voltage- 
operated Ca2+ channels and calcium released from 
these stores are involved in the contractile mecha­
nism of simvastatin. In summary, simvastatin 
might increase intracellular calcium concentration 
in both endothelial and vascular smooth muscle 
cells. This effect lead to an activation of NO syn­
thase and cyclo-oxygenase pathway in endothelial 
cells and to contraction in vascular smooth mus­
cle cells.
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